Cortistatin

What is Cortistatin?

Cortistatin is an endogenous neuropeptide cloned and characterized in 1996 by Luis de Lecea, J. Gregor Sutcliffe, and colleagues at the Scripps Research Institute, who reported the discovery in Nature on 16 May 1996. It was isolated as a transcript enriched in cortical interneurons during a directed hunt for novel cortical mRNAs, and the predicted peptide bore a 'FWKT' core sequence shared with somatostatin — the structural feature that ultimately defines its receptor pharmacology. The mature peptide exists in two physiological forms: cortistatin-14 (the predominant rodent form) and cortistatin-17/29 (the human/primate forms), both processed from a 105-residue precursor encoded by the CORT gene on human chromosome 1p36.22. Cortistatin shares 11 of 14 amino acids with somatostatin-14, including the receptor-binding FWKT motif, and binds all five somatostatin receptors (sst1-sst5) with comparable affinity to somatostatin itself. What distinguishes cortistatin pharmacologically is that it additionally binds the ghrelin receptor (GHSR1a) as an antagonist or inverse agonist (Deghenghi and colleagues), the orphan receptor MrgX2, and a cortistatin-preferring binding site that does not correspond to any cloned somatostatin receptor — a fingerprint that explains the partial divergence of cortistatin and somatostatin physiology. Anatomically, cortistatin is heavily expressed in cortical and hippocampal GABAergic interneurons (a distribution very different from the broad neuronal-and-endocrine expression of somatostatin) and in immune-system tissues including macrophages, lymphocytes, and dendritic cells, where it is co-released with cytokines during inflammatory challenge. Cortistatin's defining physiological roles are promotion of slow-wave sleep, depression of cortical neuronal firing, and anti-inflammatory immunomodulation — three lines of biology developed extensively by de Lecea and by Mario Delgado, Elena Gonzalez-Rey, and colleagues at the Spanish National Research Council in Granada. It is studied as an experimental therapeutic in chronic inflammation, autoimmune disease, atherosclerosis, and sleep disorders, but no cortistatin product has been clinically approved.

What Cortistatin Is Investigated For

Cortistatin is an endogenous-biology and drug-target topic, not a peptide consumers take. Its translational profile runs along three converging tracks. First, the sleep biology: de Lecea's original 1996 Nature paper named the peptide for its 'cortical' origin and 'somatostatin-like' structure and showed that intracerebroventricular cortistatin produced cortical EEG slow-wave activity and behavioral sleep promotion in rodents — a finding extended by Bourgin and colleagues in 2007, who linked endogenous cortistatin oscillations to slow-wave sleep stages and demonstrated that cortistatin antibodies reduce slow-wave sleep. Second, the immunology: the Granada group led by Mario Delgado and Elena Gonzalez-Rey established over 2006-2015 that cortistatin is co-expressed and co-released with cytokines in macrophages, lymphocytes, and dendritic cells, and that exogenous cortistatin administration produces robust anti-inflammatory effects in animal models of inflammatory bowel disease (PNAS 2006), sepsis, rheumatoid arthritis, multiple sclerosis, and atherosclerosis — with the 2017 Sci Reports atherosclerosis paper extending the program into ApoE-deficient mice. Third, the cardiovascular and metabolic angle: cortistatin antagonizes ghrelin at the ghrelin receptor and influences GH secretion, prolactin release, and food intake, with effects partly mirroring and partly opposing somatostatin. The honest framing is that cortistatin has an unusually rich and multidisciplinary preclinical literature for a peptide that has never reached clinical development — its translational stalling reflects pharmacokinetic challenges (short plasma half-life, poor CNS penetration of the native peptide) and the difficulty of distinguishing cortistatin-specific signaling from broader somatostatin-receptor agonism in vivo. The Granada laboratory continues to publish on cortistatin therapeutics, but as of 2026 no cortistatin product has been clinically approved for any indication.

History & Discovery

Cortistatin was discovered in 1996 by Luis de Lecea, J. Gregor Sutcliffe, and colleagues at the Scripps Research Institute in La Jolla, California. The discovery was the product of a directed effort to identify novel mRNAs enriched in cortical interneurons by subtractive cDNA hybridization — a screening approach that produced cortistatin and, separately, the hypocretin/orexin transcripts that de Lecea would help characterize two years later in another foundational paper. The cortistatin transcript encoded a peptide bearing the 'FWKT' core sequence shared with somatostatin, which immediately suggested a relationship with somatostatin signaling. The team confirmed cortistatin's broad somatostatin-receptor agonism, demonstrated that intracerebroventricular cortistatin produced cortical EEG slow-wave activity and behavioral sleep in rats, and named the peptide for its 'cortical' origin and 'somatostatin-like' structure. The 16 May 1996 Nature paper established the cortistatin field. The receptor pharmacology unfolded over the late 1990s and early 2000s. Comparative binding studies established that cortistatin binds all five somatostatin receptors (sst1-sst5) with comparable nanomolar affinity to somatostatin itself, validating the FWKT motif as the shared receptor-binding pharmacophore. Romano Deghenghi and colleagues identified cortistatin's binding to the ghrelin receptor GHSR1a as an antagonist — a finding that distinguished cortistatin from somatostatin pharmacologically and integrated it into the GH-feeding axis. Electrophysiology experiments demonstrated cortical effects that survived somatostatin-receptor blockade, supporting the existence of a cortistatin-preferring binding site that has remained molecularly uncharacterized. MrgX2 binding on mast cells and immune cells was identified later. The sleep biology was extended by Pierre Bourgin, working with de Lecea, in the 2007 European Journal of Neuroscience paper showing that endogenous cortistatin levels oscillate with slow-wave sleep stages and that intracerebral antibody blockade of cortistatin reduces slow-wave sleep. This established cortistatin not just as an exogenously administered sleep-promoting peptide but as a physiological regulator of slow-wave sleep — a finding that distinguishes cortistatin from somatostatin, which has no comparable sleep role. The immune and anti-inflammatory program was developed primarily by Mario Delgado, Elena Gonzalez-Rey, and colleagues at the Spanish National Research Council (CSIC) in Granada, beginning with their 2006 PNAS paper showing that exogenous cortistatin reduces severity of TNBS- and DSS-induced colitis in mice. Over the following decade the Granada group extended the cortistatin therapeutic program to collagen-induced arthritis, experimental autoimmune encephalomyelitis (an MS model), endotoxic shock, sepsis, and atherosclerosis (Sci Reports 2017). The 2015 Annals of the New York Academy of Sciences review by Gonzalez-Rey ('Lulling immunity, pain, and stress to sleep with cortistatin') summarized the integrated case for cortistatin as a multistep therapeutic for inflammatory and autoimmune disease. Despite an unusually broad and multidisciplinary preclinical literature, cortistatin has not advanced to clinical development. The translational challenges — short plasma half-life, limited blood-brain-barrier penetration of the native peptide, and the difficulty of distinguishing cortistatin-specific signaling from somatostatin-receptor agonism in vivo — have repeatedly slowed progression. Selective small-molecule agonists of cortistatin's distinctive non-somatostatin binding sites have not yet emerged at clinical scale. The Granada laboratory continues to publish on cortistatin therapeutics, and as of 2026 cortistatin remains one of the most thoroughly studied neuropeptides without a translational outcome.

How It Works

Cortistatin is a small protein your brain and immune cells make. It looks a lot like somatostatin (a well-known hormone that puts the brakes on growth hormone and insulin), and it binds to the same receptors. But it has two extra tricks: it slows down brain activity in the cortex, which helps generate deep slow-wave sleep, and it calms inflammation in immune cells. Researchers have shown in rodents that cortistatin promotes deep sleep and reduces the severity of colitis, arthritis, and other inflammatory conditions. It is not approved as a drug, and the doses required would also turn down growth hormone and insulin — so it is not a free lunch. Scientists are looking for ways to keep the sleep-and-anti-inflammatory effects while avoiding the somatostatin-like hormone suppression.

Cortistatin is encoded by the CORT gene on human chromosome 1p36.22, with a 105-residue prepropeptide processed to two mature forms: cortistatin-14 (the predominant rodent form, with sequence PCKNFFWKTFSSCK) and cortistatin-29 (extended N-terminally; the predominant human/primate form). The receptor-binding pharmacophore is the FWKT motif shared with somatostatin, and cortistatin shows comparable nanomolar affinity to somatostatin at all five somatostatin receptors (sst1, sst2, sst3, sst4, sst5) — a Gi/o-coupled rhodopsin-family GPCR family that broadly inhibits adenylate cyclase, activates inwardly rectifying potassium channels, and inhibits voltage-gated calcium channels. This shared sst1-sst5 agonism accounts for cortistatin's substantial overlap with somatostatin physiology, including inhibition of GH, prolactin, insulin, glucagon, and gastrointestinal secretions when administered exogenously. Cortistatin is distinguished from somatostatin by additional binding sites. It binds the ghrelin receptor GHSR1a as an antagonist or inverse agonist (Deghenghi and colleagues), opposing ghrelin's stimulation of GH release and feeding. It binds MrgX2 (a Mas-related orphan GPCR) on mast cells and immune cells with implications for neurogenic inflammation. And electrophysiology experiments have repeatedly demonstrated a cortistatin-preferring binding site in cortical neurons that does not correspond to any cloned somatostatin receptor and that mediates the cortical EEG depressant effect that distinguishes cortistatin from somatostatin behaviorally. Anatomically, cortistatin expression is heavily concentrated in cortical and hippocampal GABAergic interneurons (a distribution mapped extensively in the original 1996 Nature paper and subsequent in situ hybridization studies), in contrast to the broad neuronal-and-endocrine expression of somatostatin. In the periphery, cortistatin is expressed in macrophages, lymphocytes (particularly Th1 and Th17 cells), dendritic cells, mast cells, and gastrointestinal smooth muscle, where its expression is upregulated by inflammatory stimuli (LPS, TNF, IFN-gamma). This immune-tissue expression is the foundation for the Granada group's anti-inflammatory program. Functionally, central cortistatin administration produces cortical EEG slow-wave activity, depression of pyramidal-neuron firing rates, and behavioral sleep — effects that survive somatostatin-receptor blockade in some studies, supporting the cortistatin-specific binding site as the mediator. Bourgin and colleagues (Eur J Neurosci 2007) showed that endogenous cortistatin levels oscillate with slow-wave sleep stages in rats and that intracerebral antibody blockade of cortistatin reduces slow-wave sleep. Peripherally, cortistatin administration in animal models of inflammatory disease — TNBS and DSS colitis (Gonzalez-Rey et al., PNAS 2006), collagen-induced arthritis, experimental autoimmune encephalomyelitis, endotoxic shock, and atherosclerosis (Delgado-Maroto et al., Sci Reports 2017) — reduces inflammatory cytokine production, expands regulatory T-cell populations, inhibits Th1/Th17 polarization, and reduces histological tissue damage. The mechanistic basis combines somatostatin-receptor-mediated effects (sst2 and sst5 prominently) with cortistatin-specific pathways through GHSR1a antagonism and MrgX2-dependent mast-cell modulation. The translational challenge has been delivering cortistatin or cortistatin-pathway agonism to relevant tissues while avoiding the global somatostatin-like endocrine suppression that comes from full sst1-sst5 agonism.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Cortistatin:

• 01The molecular identity of the cortistatin-preferring central binding site — repeatedly demonstrated by electrophysiology and behavioral pharmacology to mediate cortistatin-specific effects on cortical EEG and slow-wave sleep, but not yet cloned or characterized at the molecular level after three decades of cortistatin research.
• 02Whether selective small-molecule agonists of cortistatin-specific signaling pathways (distinct from sst1-sst5 agonism) can deliver the slow-wave-sleep and anti-inflammatory benefits without the somatostatin-like endocrine suppression that would otherwise accompany peripheral administration of native cortistatin.
• 03The clinical viability of the Granada group's anti-inflammatory program — efficacy data are robust across multiple animal models of autoimmune disease, but no human trial of cortistatin or a cortistatin-pathway agonist has been completed in inflammatory bowel disease, arthritis, MS, or atherosclerosis.
• 04Whether cortistatin's age-related expression decline contributes to age-related slow-wave-sleep loss, and whether cortistatin-pathway agonism could be a strategy for restoring slow-wave sleep in older adults — a population with documented slow-wave-sleep deficits that have been linked to cognitive decline, glymphatic clearance impairment, and cardiovascular morbidity.
• 05The role of cortistatin in neurogenic inflammation and chronic pain through MrgX2 and mast-cell pathways, and whether cortistatin-pathway antagonism (rather than agonism) could be a strategy for mast-cell-driven pain syndromes.
• 06Whether the ghrelin-receptor antagonism component of cortistatin's pharmacology contributes meaningfully to its in-vivo metabolic effects, or whether somatostatin-receptor-mediated GH and insulin suppression dominate the phenotype.
• 07Whether cortistatin's effect on regulatory T-cell expansion, demonstrated repeatedly in autoimmune-disease models, could be exploited for transplantation immunology or graft-versus-host disease — applications not yet pursued in the published cortistatin program.

Forms & Administration

Cortistatin is not formulated or approved as a therapeutic in any jurisdiction. Research applications use synthetic cortistatin-14 and cortistatin-29 for in vitro receptor binding, electrophysiology, ex vivo immune-cell and tissue assays, intracerebroventricular administration in animal sleep studies, and intraperitoneal or subcutaneous administration in animal inflammation models. Selective small-molecule agonists of cortistatin-specific binding sites (distinct from somatostatin receptors) have not progressed to clinical-stage assets. Compounded cortistatin from peptide marketplaces has no validated clinical use.

Common Questions

Who Cortistatin Is NOT For

Drug & Supplement Interactions

There is no validated human drug-interaction profile for cortistatin because no cortistatin product has been clinically developed. Theoretical interactions extrapolate from the somatostatin-analog class (octreotide, lanreotide, pasireotide) and from cortistatin's distinctive ghrelin-receptor antagonism. Like approved somatostatin analogs, cortistatin would be expected to suppress insulin and glucagon release with potential interaction with diabetes medications (insulin, sulfonylureas, DPP-4 inhibitors, GLP-1 agonists), suppress GH and IGF-1 with interaction implications for GH replacement, and reduce gastric acid secretion and gallbladder contractility with relevance to PPIs and biliary disease management. Cortistatin's antagonism at the ghrelin receptor could oppose appetite-stimulating effects of ghrelin-receptor agonists (relamorelin, anamorelin, MK-677) used in cachexia and post-operative ileus indications. Co-administration with other somatostatin analogs would produce additive sst1-sst5 agonism with amplified endocrine suppression. None of these interactions has been characterized for cortistatin in controlled human studies; they are mechanistic possibilities argued from receptor pharmacology that argue against casual exogenous cortistatin exposure outside controlled research.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions